Table S1 Pharmacokinetic parameters of metformin

	C_{max} (μM)	T_{max} (h)	AUC_{inf}[a] (μM×h)	f_e[b]	$T_{1/2}$ (h)	CL/F[c] (ml/min)	$CL_{r,p}$[d] (ml/min)	F[e]	V_d/F[f] (L)
Control	12.0±2.8	2.67±0.99	75.0±13.6	0.683±0.110	4.83±0.56	692±130	471±52.7	0.542±0.086	266±55
+PYR10mg	11.5±2.6	2.00±0.74	78.7±12.0	0.619±0.125	6.98±1.45	654±102	416±61.7	0.505±0.097	269±46
+PYR25mg	15.3±6.9	2.83±1.03	97.2±26.7	0.566±0.232	6.92±1.56	552±143	317±74.7	0.461±0.094	233±68
+PYR75mg	18.5±7.7	3.00±1.04	132±35	0.530±0.146	6.23±0.92	406±113	213±31.7	0.430±0.113	180±61

[a.] AUC_{inf} was calculated as $AUC_{0\text{-}24h} + C_{24h}/(\ln 2/T_{1/2})$

[b.] f_e was calculated as $X_{urine}(0\text{-}24h)/Dose$

[c.] CL/F was calculated as $Dose/AUC_{inf}$

[d.] $CL_{r,p}$ was calculated as $X_{urine}(0\text{-}24h)/AUC_{0\text{-}24h}$

[e.] F was calculated as $CL_r/(CL/F)$

[f.] V_d/F was calculated as CL/F×MRT

Each parameter was shown as arithmetic mean ± SEM. Statistical significance in the difference in the pharmacokinetic parameters between control and pyrimethamine-treated conditions was shown in Supplemental TableS2.

Parameters: C_{max}, maximum plasma concentration; T_{max}, time to achieve the maximum concentration; AUC_{inf}, AUC from time 0 to infinity; f_e, fraction recovered in the urine; $T_{1/2}$, half-life at the terminal phase; CL/F, oral clearance; CL_r, renal clearance; F, bioavailability; V_d/F, apparent volume of distribution; MRT, mean residence time